Raymond James Maintains Outperform on Knight Therapeutics, Raises Price Target to $7.5
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst David Novak has maintained an Outperform rating on Knight Therapeutics (OTC:KHTRF) and raised the price target from $7 to $7.5.
March 06, 2024 | 5:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James has maintained an Outperform rating on Knight Therapeutics and increased the price target to $7.5.
The maintenance of an Outperform rating combined with an increased price target typically signals a positive outlook on the stock by analysts, which can lead to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100